Showing 1471-1480 of 1735 results for "".
- Gottlieb, Mostashari Propose National COVID-19 Surveillance Systemhttps://modernod.com/news/gottlieb-mostashari-propose-national-covid-19-surveillance-system/2477555/Five healthcare experts—including former top government healthcare officials Scott Gottlieb and Farzad Mostashari—have proposed a plan to build a national COVID-19 surveillance system, according to a FierceHealthcare
- Trump to Nominate Stephen Hahn, Cancer Researcher, to Head FDAhttps://modernod.com/news/trump-to-nominate-stephen-hahn-cancer-researcher-to-head-fda/2477068/President Trump said Friday that he intended to nominate Stephen M. Hahn, MD, a top executive at The University of Texas M.D. Anderson Cancer Center, to be the next commissioner of the Food and Drug Administration, according to a
- Wills Eye Hospital Named #1 Ophthalmology Training Program In Americahttps://modernod.com/news/wills-eye-hospital-named-1-ophthalmology-training-program-in-america/2479536/Wills Eye Hospital has taken top honors again this year for the best residency training program in the United States for ophthalmologists. Doximity, which coordinates the vote, is the largest online physician network and is a navigator for medical students conside
- Takeda Gets Japanese Approval for $62 Billion Shire Purchasehttps://modernod.com/news/takeda-gets-japanese-approval-for-62-billion-shire-purchase/2479773/Takeda Pharmaceutical reported that Japan’s Fair Trade Commission had approved its $62 billion acquisition of Shire, bringing the Japanese firm closer to sealing a deal that will make it a global top 10 drugmaker, according to
- J&J Launches Daily Disposable Multifocal Toric Contact Lens: Acuvue Oasys Max 1-Day Multifocal for Astigmatismhttps://modernod.com/news/johnson-johnson-launches-daily-disposable-multifocal-toric-contact-lens-acuvue-oasys-max-1-day-multifocal-for-astigmatism/2482858/Johnson & Johnson announced the launch of Acuvue Oasys Max 1-Day Multifocal for Astigmatism, a daily disposable contact lens for people with both astigmatism and presbyopia. The company says this contact lens provides patients crisp, clear, stable vision at all distances and in all
- Sifi Launches Well Fusion Presbyopia Correcting Systemhttps://modernod.com/news/sifi-launches-well-fusion-presbyopia-correcting-system/2478688/SIFI announces the launch of the Well Fusion system and the Mini Well Proxa IOL, offering a novel solution that provides cataract patients the option to treat presbyopia with spectacle-free uninterrupted high-quality vision at all distances and in all lighting conditions. SIFI has develope
- Toku Obtains CE and UKCA Marks for AI Cardiovascular Risk Assessments Through the Eyehttps://modernod.com/news/toku-obtains-ce-and-ukca-marks-for-ai-cardiovascular-risk-assessments-through-the-eye/2482096/Toku announced that it has obtained CE Mark in Europe and UKCA in the United Kingdom for its patented CLAiR technology, which provides a non-invasive evaluation for the risk of cardiovascular disease (CVD) at the point of care using retinal images captured during a routine eye exam
- Orcam Technologies Unveils Orcam Read 3 AI-Driven Solution for People with Low Vision and Visual Impairmentshttps://modernod.com/news/orcam-technologies-unveils-orcam-read-3-ai-driven-solution-for-people-with-low-vision-and-visual-impairments/2481965/OrCam Technologies has introduced the OrCam Read 3, which is designed to improve the way people with vision loss and reading difficulties interact with visual materials. User point the device at a book, computer screen, product packaging or any text, and the AI technology will loudly and cle
- FDA Grants Breakthrough Device Status to Toku’s Patented Cardiovascular Risk AI (CLAiR) Platformhttps://modernod.com/news/fda-grants-breakthrough-device-status-to-tokus-patented-cardiovascular-risk-ai-clair-platform/2481934/Toku announced that the FDA has granted Breakthrough Device designation to its patented CLAiR technology. According to Toku, the CLAiR platform, if cleared by the FDA, will be the first medical device in the US market that can provide affordable, point-of-care and non-invasive
- In Final Rule, CMS Rejects Proposal to Make Facility Payments for Office-Based Ophthalmic Surgerieshttps://modernod.com/news/in-final-rule-cms-rejects-proposal-to-make-facility-payments-for-office-based-ophthalmic-surgeries/2481218/In its Medicare Physician Fee Schedule Final Rule for 2023, CMS rejected a proposal to make facility payments for office-based ophthalmic surgeries. The following is a summary of this and other key points in the ruling. Office-based payments. In response to requests to